Citigroup
FLGT icon

Citigroup’s Fulgent Genetics FLGT Stock Holding History

Citigroup’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
56,246
+38,841
+223% +$658K ﹤0.01% 3336
2026
Q1 		$277K Buy
17,405
+16,810
+2,825% +$365K ﹤0.01% 3841
2025
Q4 		$15.6K Sell
595
-4,238
-88% -$110K ﹤0.01% 4930
2025
Q3 		$109K Sell
4,833
-10,447
-68% -$215K ﹤0.01% 4236
2025
Q2 		$304K Sell
15,280
-14,452
-49% -$282K ﹤0.01% 3870
2025
Q1 		$502K Sell
29,732
-6,735
-18% -$115K ﹤0.01% 3676
2024
Q4 		$674K Buy
36,467
+3,375
+10% +$65.9K ﹤0.01% 3624
2024
Q3 		$719K Buy
33,092
+10,236
+45% +$229K ﹤0.01% 3503
2024
Q2 		$448K Buy
22,856
+2,173
+11% +$45.4K ﹤0.01% 3467
2024
Q1 		$449K Buy
20,683
+6,406
+45% +$159K ﹤0.01% 3645
2023
Q4 		$413K Buy
14,277
+4,739
+50% +$127K ﹤0.01% 3544
2023
Q3 		$255K Sell
9,538
-6,418
-40% -$219K ﹤0.01% 3528
2023
Q2 		$591K Buy
15,956
+5,103
+47% +$178K ﹤0.01% 3250
2023
Q1 		$339K Sell
10,853
-4,856
-31% -$156K ﹤0.01% 3411
2022
Q4 		$468K Buy
15,709
+4,847
+45% +$173K ﹤0.01% 3224
2022
Q3 		$414K Buy
10,862
+610
+6% +$30.6K ﹤0.01% 3371
2022
Q2 		$559K Sell
10,252
-9,900
-49% -$544K ﹤0.01% 3127
2022
Q1 		$1.26M Buy
20,152
+702
+4% +$46.2K ﹤0.01% 2741
2021
Q4 		$1.96M Buy
19,450
+606
+3% +$53.3K ﹤0.01% 2639
2021
Q3 		$1.7M Buy
18,844
+366
+2% +$33.3K ﹤0.01% 2673
2021
Q2 		$1.7M Buy
18,478
+16,960
+1,117% +$1.35M ﹤0.01% 2783
2021
Q1 		$147K Sell
1,518
-1,774
-54% -$183K ﹤0.01% 4186
2020
Q4 		$172K Buy
3,292
+2,827
+608% +$118K ﹤0.01% 5097
2020
Q3 		$19K Sell
465
-872
-65% -$27.3K ﹤0.01% 6229
2020
Q2 		$21K Sell
1,337
-523
-28% -$8.01K ﹤0.01% 6569
2020
Q1 		$20K Buy
1,860
+912
+96% +$12.7K ﹤0.01% 6686
2019
Q4 		$12K Buy
+948
New +$11.3K ﹤0.01% 7137
2017
Q2 		– Sell
-171
Closed -$2K – 7377
2017
Q1 		$2K Sell
171
-22,709
-99% -$268K ﹤0.01% 6991
2016
Q4 		$265K Buy
+22,880
New +$216K ﹤0.01% 5042

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup's FLGT Position: Q2 2026 in Review

Citigroup increased its Fulgent Genetics (FLGT) stake by 223% in Q2 2026, buying an estimated $658K and bringing the position to 56,246 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3336.

Citigroup first reported a position in FLGT in Q4 2016 and has held it in 29 quarters since. The position peaked at $1.96M in Q4 2021. 142 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • Citigroup held 56,246 shares of Fulgent Genetics worth $1.15M as of Q2 2026.
  • Citigroup bought 38,841 Fulgent Genetics shares in Q2 2026, an estimated $658K.
  • Fulgent Genetics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3336 holding.
  • Citigroup first reported a position in Fulgent Genetics in Q4 2016 and has held it in 29 quarters since.
  • Citigroup's Fulgent Genetics position peaked at $1.96M in Q4 2021.
  • 142 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.